Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBK1 | Q9UHD2 | 19/20 | 0.67 |
| ▸ | PDPK1 | O15530 | 4/20 | 0.67 |
| ▸ | STK17A | Q9UEE5 | 3/20 | 0.52 |
| ▸ | MARK3 | P27448 | 2/20 | 0.52 |
| ▸ | MARK4 | Q96L34 | 2/20 | 0.52 |
| ▸ | STK17B | O94768 | 1/20 | 0.45 |
| ▸ | TYK2 | P29597 | 1/20 | 0.45 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.45 |
| ▸ | SIK2 | Q9H0K1 | 1/20 | 0.45 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1285158 | 0.90 | TBK1 (0.60) | TBK1PDPK1STK17AMARK3MARK4 | |
| SCHEMBL15163133 | 0.89 | TBK1 (0.52) | TBK1PDPK1 | |
| SCHEMBL1285231 | 0.88 | TBK1 (0.58) | TBK1PDPK1STK17AMARK3MARK4 | |
| SCHEMBL1618001 | 0.88 | TBK1 (0.58) | TBK1PDPK1STK17AMARK3MARK4 | |
| SCHEMBL1285556 | 0.85 | TBK1 (0.72) | TBK1PDPK1STK17AMARK3MARK4 | |
| SCHEMBL1285068 | 0.83 | TBK1 (0.69) | TBK1PDPK1STK17AMARK3MARK4 | |
| SCHEMBL15163202 | 0.81 | CDK4 (0.45) | TBK1PDPK1TYK2 | |
| SCHEMBL13432168 | 0.80 | TBK1 (1.00) | TBK1PDPK1STK17AMARK3MARK4 | |
| SCHEMBL15163200 | 0.80 | CDK4 (0.46) | TBK1PDPK1STK17ATYK2 | |
| SCHEMBL15163281 | 0.79 | TBK1 (0.46) | TBK1PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088753-A1 | PYRROLOPYRIMIDINES AND USED AS KINASE INHIBITORS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2012-04-12 | — | — | US | claimed |
| EP-2403853-B1 | PYRROLOPYRIMIDINES USED AS KINASE INHIBITORS | MEDICAL RES COUNCIL TECHNOLOGY (GB) | 2013-08-14 | — | — | EP | disclosed |
| US-20120088753-A1 | PYRROLOPYRIMIDINES AND USED AS KINASE INHIBITORS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2012-04-12 | — | — | US | disclosed |
| US-20120088753-A1 | PYRROLOPYRIMIDINES AND USED AS KINASE INHIBITORS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2012-04-12 | — | — | US | disclosed |
| US-20120088753-A1 | PYRROLOPYRIMIDINES AND USED AS KINASE INHIBITORS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2012-04-12 | — | — | US | disclosed |
| WO-2010100431-A1 | PYRROLOPYRIMIDINES USED AS KINASE INHIBITORS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2010-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088753-A1 | PYRROLOPYRIMIDINES AND USED AS KINASE INHIBITORS | MARK3, MAPK8, CDK8 | TBK1 17/4885PDPK1 280/4885STK17A 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.